{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'patient from the study at any time for any reason (eg, protocol violation or deviation as defined', 'in Section 11.1.2, noncompliance, or adverse event).', 'Please see Section 4.4 for the withdrawal criteria and procedures.', '3.12.', 'Source Data Recorded on the Case Report Form', 'All patient data must have supportive original source documentation in the medical records, or', 'equivalent, before they are transcribed onto the CRF. Data may not be recorded directly onto the', 'CRF and considered as source data unless the sponsor provides written instructions specifying', 'which data are permitted to be recorded directly onto the CRF, such as eScales.', 'If patient data are processed from other vendors (eg, clinical laboratory, central ECG, diary data),', 'the results will be sent to the investigational center, where they will be retained but not entered', 'into the CRF. These data may also be sent electronically to the sponsor (or organization', 'performing data management) for direct use with the clinical database (see Section 13.1). All', 'clinical patient data from other vendors will be available to the investigator.', \"The CRFs are filed in the sponsor's central file after study completion.\", '3.13.', 'Study Procedures', 'Study procedures and assessments with their time points are presented in Table 1. During a visit,', 'study procedures and assessments should be performed in the order specified in the study', 'manual.', 'Detailed by-visit information is provided in the sections following the table. Detailed', 'descriptions of each assessment are provided in Section 6 (efficacy assessments), Section 7', '(safety assessments), and Section 8 (pharmacokinetic and other assessments).', '51']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 1:', 'Study Procedures and Assessments', 'Screening', 'BLa', 'Titration', 'Maintenance', 'Follow-up', 'U', 'Study weekb', 'Up to', 'Day', '1', '2', '3', '4', '5', '6', '7', '9', '12/ET\u00b0', '13', '14e', '31 days', '1c', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '7)', '14)', '21)', '28)', '35)', '42)', '49)', '63)', '84)', '91', '98)', 'Visit window (days)', '0', '3 days', '3 days from', 'days', 'Week 12', 'In-clinic visit', 'Xf', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Telephone contact', 'X', 'X', 'X', 'X', 'X', 'Evaluate/Adjust IMP', 'Xg', 'X', 'Xg', 'X', 'Xg', 'X', 'X', 'Informed consent/assent', 'X', 'Eligibility criteria', 'X', 'X', 'Medical history and psychiatric', 'X', 'history', 'Demographics', 'X', 'Vital signs and weighth', 'X', 'Xi', 'X', 'Xi', 'X', 'X', 'Xi', 'X', 'Physical examination', 'X', 'X', 'Neurological examination', 'X', 'X', 'Height', 'X', 'X', '12-lead ECGK', 'X', 'X', 'X', 'X', 'X', 'Pharmacokinetic blood sampling', 'X\u00b9', 'Chemistry/Hematology/Urinalysis', 'X', 'X', 'Xm', 'Urine drug screen', 'X', 'X', 'Randomization', 'X', 'CYP2D6 genotype\"', 'X', '\u00df-HCG test\u00b0', 'X', 'X', 'Xj', '52']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 1:', 'Study Procedures and Assessments (Continued)', 'Screening', 'BLa', 'Titration', 'Maintenance', 'Follow-up', 'U', 'Study weekb', 'Up to', 'Day', '1', '2', '3', '4', '5', '6', '7', '9', '12/ET\u00b0', '13', '14e', '31 days', '1c', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '7)', '14)', '21)', '28)', '35)', '42)', '49)', '63)', '84)', '91', '98)', 'Visit window (days)', '0', '3 days', '3 days from', 'days', 'Week 12', 'MINI Kidp,g', 'X', 'CDI-2 (Parent and Self-report)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X\u00b9', \"C-SSRS (Children's\", 'X', 'Baseline/Screen)', \"C-SSRS (Children's Since Last\", 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Xj', 'Visit)', 'YGTSS,', 'X', 'X', 'Xu', 'X', 'Xu', 'Xu', 'X', 'Xu', 'TS-CGIt', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'TS-PGIIt', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 't', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'XV', 'X', 'XY', 'C&A-GTS-QOL', 'X', 'X', 'X', 'Dispense IMPW', 'XX', 'XX', 'XX', 'Xy', 'Xy', 'Collect IMP', 'X', 'X', 'X', 'X', 'Xi', 'Assess IMP', 'X\u00b2', 'X', 'X2', 'X', 'X\u00b2', 'X', 'X\u00b2', 'X', 'X', 'X\u00b9', 'accountability/compliance/suppli', 'Assess adverse events', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications', 'X', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'a', 'The baseline visit will occur on the same day as the scheduled first dose of the IMP (day 1).', '53']\n\n###\n\n", "completion": "END"}